Follicular Lymphoma
📧 Sign up to get email alerts when something new happens for Follicular Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-04-08Clinical Trial Update: To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma [Phase 3]
Phase 3 trial comparing CT-P10 to Rituxan in low tumor burden follicular lymphoma has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-03-19Clinical Trial Update: Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL) [Phase 1]
Phase 1 trial in Japanese participants assessing safety, tolerability, and pharmacokinetics of idelalisib in relapsed or refractory indolent…
-
CLINICAL_TRIALS withdrawal · 2021-03-17Clinical Trial Update: A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) [Phase 3]
Phase 3 trial BRAVURA evaluating duvelisib with rituximab and bendamustine versus placebo in indolent non-Hodgkin lymphoma was withdrawn.
-
CLINICAL_TRIALS trial_result · 2021-03-01Clinical Trial Update: Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma [Phase 2]
Phase 2 trial evaluating sequential intranodal immunotherapy with anti-PD1 pembrolizumab in follicular lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2021-02-23Clinical Trial Update: Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma [Phase 2]
Phase 2 trial evaluating bendamustine with rituximab, with or without bortezomib, followed by rituximab with or without lenalidomide in high…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-01-28Clinical Trial Update: Efficacy and Safety of SHC014748M in Patients With Relapsed or Refractory Follicular (FL) or Marginal Zone (MZL) Lymphoma [Phase 2]
Phase 2 clinical trial assessing SHC014748M for relapsed or refractory follicular lymphoma and marginal zone lymphoma.
-
CLINICAL_TRIALS trial_result · 2021-01-13Clinical Trial Update: A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma [Phase 2]
A Phase 2 clinical trial update evaluating safety and efficacy of duvelisib in relapsed/refractory follicular lymphoma.
-
CLINICAL_TRIALS trial_result · 2021-01-12Clinical Trial Update: Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma [Phase 2]
Phase 2 trial of atezolizumab with or without low-dose local radiation in relapsed/refractory advanced-stage follicular lymphoma was termina…
-
FDA approval · 2020-12-17FDA Approved: RIABNI — Original Application (Amgen, Inc)
FDA approved RIABNI (rituximab-arrx) from Amgen as a biosimilar to rituximab via Original Application.
-
CLINICAL_TRIALS withdrawal · 2020-12-17Clinical Trial Update: Evaluate the Efficacy and Safety of HLX01 Versus Mabthera in Patients With Low Tumour Burden Follicular Lymphoma. [Phase 3]
A Phase 3 trial comparing HLX01 to Mabthera in CD20-positive follicular lymphoma with low tumor burden was withdrawn.
-
CLINICAL_TRIALS trial_result · 2020-10-29Clinical Trial Update: Study of Vorinostat (MK-0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL), or Mantle Cell Lymphoma (MCL) Participants (MK-0683-103) [Phase 2]
Phase 2 study MK-0683-103 evaluated vorinostat in follicular lymphoma, other indolent B-cell non-Hodgkin lymphomas, and mantle cell lymphoma…
-
CLINICAL_TRIALS trial_result · 2020-10-08Clinical Trial Update: A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma [Phase 3]
Phase 3 trial comparing SAIT101 to Rituximab as first-line immunotherapy in low tumor burden follicular lymphoma has completed with results …
-
CLINICAL_TRIALS trial_result · 2020-09-23Clinical Trial Update: Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies [Phase 2]
Phase 2 study evaluating entospletinib in adults with relapsed or refractory hematologic malignancies; study terminated with posted results.
-
CLINICAL_TRIALS trial_result · 2020-09-23Clinical Trial Update: Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma [Phase 1]
Phase 1 trial evaluating pembrolizumab with combination chemotherapy in untreated diffuse large B-cell lymphoma and grade 3b follicular lymp…
-
CLINICAL_TRIALS trial_result · 2020-08-13Clinical Trial Update: A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) [Phase 3]
Phase 3 study evaluating safety, efficacy, and pharmacokinetics of Rituximab in diffuse large B-cell lymphoma and follicular lymphoma has co…
-
CLINICAL_TRIALS trial_result · 2020-07-01Clinical Trial Update: A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL) [Phase 2]
Phase 2 clinical trial update for TQ-B3525 in relapsed/refractory follicular lymphoma.
-
CLINICAL_TRIALS trial_result · 2020-05-12Clinical Trial Update: Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas [Phase 1, Phase 2]
Phase 1/2 trial evaluating pembrolizumab in patients with diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma who f…
-
CLINICAL_TRIALS trial_result · 2020-05-11Clinical Trial Update: A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma [Phase 2]
A Phase 2 clinical trial update for YY-20394 in participants with relapsed/refractory follicular lymphoma.
-
CLINICAL_TRIALS trial_result · 2020-05-07Clinical Trial Update: Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia [Phase 2]
Phase 2 safety and tolerability study of PCI-32765 in various B-cell malignancies completed; results posted.
-
CLINICAL_TRIALS trial_result · 2020-05-07Clinical Trial Update: A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma [Phase 2]
Phase 2 clinical study of YY-20394 in patients with relapsed/refractory Follicular Lymphoma is in progress with unknown status.
-
FDA approval · 2020-05-05FDA Approved: RITUXAN HYCELA — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for Rituxan HYCELA (rituximab and hyaluronidase) from Genentech, expanding its approval through …
-
CLINICAL_TRIALS trial_result · 2020-04-29Clinical Trial Update: A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants [Phase 1, Phase 2]
Phase 1/2 study of idasanutlin in combination with obinutuzumab for relapsed/refractory follicular lymphoma and with rituximab for relapsed/…
-
CLINICAL_TRIALS trial_result · 2020-04-28Clinical Trial Update: ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®) [Phase 2]
Phase 2 trial updating consolidation strategies in previously untreated follicular lymphoma comparing 90Y-ibritumomab tiuxetan (Zevalin) con…
-
CLINICAL_TRIALS trial_result · 2020-04-03Clinical Trial Update: Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma [Phase 2]
Phase 2 trial investigating bendamustine, mitoxantrone, and rituximab (BMR) in untreated high-risk follicular lymphoma; study terminated wit…
-
CLINICAL_TRIALS trial_result · 2020-03-23Clinical Trial Update: Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating everolimus and lenalidomide in relapsed or refractory non-Hodgkin or Hodgkin lymphoma; results posted.